TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07552987: A Phase III, Randomized, Double-blind, Placebo-Controlled, Parallel Group, Multicenter Study to Assess the Efficacy and Safety of Intravenous Human Normal Immune Globulin (IGIV) 10% in Adult Patients With Stiff Person Sy

Sponsor: Kedrion S.p.A. · Phase: PHASE3 · Area: IMMUNOLOGY · Target Enrollment: 38 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$15,676,800

Rescue Site Savings

+$10,336,890

Unlock Full NCT07552987 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07552987 Rescue Dossier →